Patient info Open main menu

‘Fam-Lax Phenolphthalein' Tablets – Summary of Product Characteristics (SmPC) for healthcare professionals

Last updated: · Text from the MHRA, as of · About this document

Medicine status: No longer supplied Details

The Summary of Product Characteristics (SmPC) is written for healthcare professionals. Patients will find plain advice in the patient information leaflet: how to take, side effects, other medicines, pregnancy and breast-feeding.

Medicine strength:
120 mg + 27.5 mg
Contains active substances:

Summary of Product Characteristics (SmPC) - Fam-lax Phenolphthalein tablets

1 NAME OF THE MEDICINAL PRODUCT

‘Fam-Lax Phenolphthalein' Tablets.

2 QUALITATIVE AND QUANTITATIVE COMPOSITION

Active Constituents :

Quantity per tablet

Yellow Phenolphthalein USP 120 mg

Powdered Rhubarb BP 27.5 mg

3 PHARMACEUTICAL FORM

Brown circular tablets embossed with the letter T.

4 CLINICAL PARTICULARS

4.1 Therapeutic indications

Symptomatic relief from constipation.

4.2 Posology and method of administration

‘Fam-Lax Phenolphthalein’ Tablets are for oral administration.

Adults, The Elderly and Children over 12 years of age :

Half to 1 tablet daily to be taken at bedtime.

Children under 12 years of age : Not recommended.

Directions : The tablet may be chewed or crushed and taken with the aid of water, milk or fruit juice.

4.3 Contraindications

There are no known contra-indications.

4.4 Special warnings and precautions for use

Prolonged use should be avoided.

4.5 Interaction with other medicinal products and other forms of interaction

There are no known interactions.

4.6 Fertility, Pregnancy and lactation

There are no contra-indications to the administration of ‘Fam-Lax Phenolphthalein’ Tablets during pregnancy and lactation, however as with all drugs, therapy during the first trimester of pregnancy should be avoided.

4.7 Effects on ability to drive and use machines

None known.

4.8 Undesirable effects

Phenolphthalein Abdominal cramps may occasionally occur. Allergic reactions have been reported. Cardiac and respiratory distress and renal damage have also been reported.

4.9 Overdose

Overdosage can result in diarrhoea with excessive loss of water and electrolytes, particularly potassium. Treat symptomatically. There is also the possibility of developing an atonic non-functioning colon.

5 PHARMACOLOGICAL PROPERTIES

5.1 Pharmacodynamic properties

Phenolphthalein is an irritant purgative, usually taken at night to act in the morning.

Rhubarb is a mild anthraquinone purgative. It differs from other anthraquinone purgatives in that it exerts an astringent action after purgation.

5.2 Pharmacokinetic properties

Phenolphthalein is a diphenylmethane stimulant laxative. Up to 15% of phenolphthalein given by mouth is absorbed. Enterohepatic circulation occurs and the active glucuronide is excreted in the bile.

Some excretion occurs in the urine. Phenolphthalein usually has an effect within six to eight hours but because of enterohepatic circulation its action may continue for several days. Rhubarb is an anthraquinone laxative. The active anthraquinones are liberated into the colon from the glycosides by colonic bacteria and an effect usually occurs 6 to 12 hours after administration. There is some absorption of the anthraquinones following hydrolysis. Excretion occurs in the urine and the faeces and also in other secretions including milk.

5.3 Preclinical safety data

No remarks.

6 PHARMACEUTICAL PARTICULARS

6.1 List of excipients

Icing Sugar, Cocoa Powder, Powdered Acacia BP, Vanillin Ph.Eur., Peppermint Oil Ph.Eur., Stearic Acid BP, Purified Talc Ph.Eur.

6.2 Incompatibilities

None known.

6.3 Shelf life

Five years from the date of manufacture.

6.4 Special precautions for storage

Five years from the date of manufacture.

6.5 Nature and contents of container

For 12, 30 and 36 tablet pack sizes - strip foil packaging having the following specifications:

  1. a) 0.03 mm Aluminium Foil, 0.02 mm Surlyn

or

  1. b)

    40 G SM Paper 12 0 SM Polythene

    0.008 mm Aluminium Foil 25 G SM Paper

Each strip contains six tablets. Two, five or six strips are packed into an outer cardboard box.

For 9 tablet pack size - metal plate tin containing nine tablets. The tin is packed into an outer cardboard box.

6.6 Special precautions for disposal

Not applicable.

7 MARKETING AUTHORISATION HOLDER

Typharm Limited

Unit 14D Wendover road

Rackheath Industrial

Estate Rackheath

Norwich

NR13 6LH

United Kingdom

8 MARKETING AUTHORISATION NUMBER(S)

PL 00551/0226

9 DATE OF FIRST AUTHORISATION/RENEWAL OF THE

AUTHORISATION

22nd May 1996

10 DATE OF REVISION OF THE TEXT

07/03/2014

About this document

Source: MHRA - Medicines and Healthcare products Regulatory Agency (products.mhra.gov.uk) · Marketing authorisation: PL 00551/0226

Last revision stated in the text: 7 March 2014 · MHRA data as of 13 October 2026

Found a mistake? Tell us on the contact page.

The information on this site does not replace the advice of a doctor or pharmacist.

Facts about Fam-lax Phenolphthalein tablets

Active substances Phenolphthalein, Rhubarb
Strength 120 mg + 27.5 mg
Pharmaceutical form Oral tablet
How is it taken Oral
Excipients Icing Sugar, Cocoa Powder, Powdered Acacia BP, Vanillin Ph.Eur., Peppermint Oil Ph.Eur., Stearic Acid BP, Purified Talc Ph.Eur.
Is it available? No, all its packs are listed as discontinued (NHS Dictionary of Medicines and Devices – not a record of current supplies)
Shelf life Five years from the date of manufacture.
Storage Five years from the date of manufacture.
Drug group (ATC)
  1. A Alimentary tract and metabolism drugs
    1. A06 Drugs for constipation
      1. A06A Drugs for constipation
        1. A06AB Contact laxatives
          1. A06AB04 phenolphthalein
Marketing authorisation PL 00551/0226 (first authorised 22 May 1996)
Marketing authorisation holder Typharm Limited
Codes BNF 01060200

Sources: the MHRA product information (products.mhra.gov.uk) and the NHS Dictionary of Medicines and Devices (dm+d), release 10.2.0 of 19 October 2026, NHS Business Services Authority. Contains public sector information licensed under the Open Government Licence v3.0.